Boehringer Ingelheim International Gmbh

Flatiron Health, Inc.

Yihua Zhao

Holger Rosenbrock

Lauren Sutton

Jessie Tseng

Neal Meropol

Filip Frahm

Trevor Royce

Barry Leybovich

Jana Podhorna

Forrest Xiao

Maneet Kaur

Adam Gottesman

Sun Young Yum

Alex Deyle

The invention relates to the treatment of cognitive impairment associated with schizophrenia (CIAS) with a specific GlyT1 inhibitor ([5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone). A 12-week treatment in a phase 2 study showed improvement in cognitive function as measured by the MATRICS Consensus Cognitive Battery (MCCB) overall composite score.

Treatment of cognitive impairment associated with schizophrenia

Described herein is a graphical intervention test development system. The graphical intervention test development system provides a graphical intervention test development environment that facilitates computer-based design of an intervention test. The graphical intervention test development environment provides a graphical user interface (GUI) and visualizations of various aspects of an intervention test therein. The graphical intervention test development environment further provides a control interface through which a user can manipulate control parameters that affect outcomes of the intervention test.

Graphical intervention test development system

Growing community of inventors

Bedford, NY, United States of America

Yihua Zhao